Albumin Baxalta 50 g/ L Norge - norsk - Statens legemiddelverk

albumin baxalta 50 g/ l

baxalta innovations gmbh - albumin, humant - infusjonsvæske, oppløsning - 50 g/ l

Ceprotin Den europeiske union - norsk - EMA (European Medicines Agency)

ceprotin

takeda manufacturing austria ag - humant protein c - purpura fulminans; protein c deficiency - antithrombotic agents - ceprotin is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.

MS-H Vaccine Den europeiske union - norsk - EMA (European Medicines Agency)

ms-h vaccine

pharmsure veterinary products europe ltd - mycoplasma synoviae stamme ms-h - immunologicals for aves, live bakteriell vaksiner - kylling - for aktiv immunisering av fremtidige kyllingfôrkyllinger, fremtidige lagfôrkyllinger og fremtidige lagkyllinger for å redusere luftsukleskader og redusere antall egg med unormal skalldannelse forårsaket av mycoplasma synoviae.

Human Albumin Biotest 200 g/ L Norge - norsk - Statens legemiddelverk

human albumin biotest 200 g/ l

biotest pharma gmbh - humanalbumin - infusjonsvæske, oppløsning - 200 g/ l

Venticoll 0.5 mg Norge - norsk - Statens legemiddelverk

venticoll 0.5 mg

ge healthcare as - albumin, humant, kolloidale partikler - pulver til inhalasjonsvæske til nebulisator, oppløsning - 0.5 mg

Nanocoll - Norge - norsk - Statens legemiddelverk

nanocoll -

ge healthcare as - albumin humant kolloidale partikler ad tc-99m albumin nanokolloid - pulver til injeksjonsvæske, suspensjon

Flexbumin 200 g/ L Norge - norsk - Statens legemiddelverk

flexbumin 200 g/ l

baxalta innovations gmbh - albumin, humant - infusjonsvæske, oppløsning - 200 g/ l

Porcilis PCV M Hyo Den europeiske union - norsk - EMA (European Medicines Agency)

porcilis pcv m hyo

intervet international b.v. - svin circovirus type 2 (pcv2) orf2 subunit antigen, mycoplasma hyopneumoniae j belastning inaktivert - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - griser (for fetende) - for den aktive vaksinering av griser for å redusere viraemia, virus legg i lungene og lymfoide vev, virus shedding forårsaket av svin circovirus type 2 (pcv2) infeksjon, og alvorlighetsgraden av lunge lesjoner forårsaket av mycoplasma hyopneumoniae-infeksjon. for å redusere tapet av daglig vektøkning i sluttperioden i møte med infeksjoner med mycoplasma hyopneumoniae og / eller pcv2 (som observert i feltstudier).

Nanotop 0.5 mg Norge - norsk - Statens legemiddelverk

nanotop 0.5 mg

rotop pharmaka gmbh - albumin, humant, nanokolloidale partikler - preparasjonssett til radioaktive legemidler - 0.5 mg

Mhyosphere PCV ID Den europeiske union - norsk - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - griser - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.